Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib succinate in ALK/ROS1-positive NSCLC and advanced solid tumors
CTR20160340Phase 2Completed
- Sponsor
- Shanghai Institute of Materia Medica
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), Nonhematologic neoplasms, sponsored by Shanghai Institute of Materia Medica. Started Jun 2016; status: completed.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20160340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160340.